The firms said that Bio-Techne's Ella platform provides the sensitivity needed to provide analysis of the Nf-L biomarker for neurodegenerative diseases.
Quanterix said that the acquisition will secure the supply of neurofilament light antibodies that are critical to its Simoa assays and services.
Q-State Biosciences, which focuses on neurologic disorders, will work closely with WuXi NextCode to relaunch Claritas' exome assays.
The Martinos Center, Envision Genomics, and startup RowAnalytics are building an open precision medicine platform called Giro Health on IBM architecture.
ImmunArray will use Quanterix's Simoa single-molecule array technology for biomarker analysis, with the potential to enrich its diagnostic panels.